Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer

F. S. Mennini, A. Marcellusi, G. Fabiano, F. Platini, P. Bossi

Research output: Contribution to journalArticlepeer-review

Abstract

Background: In recurrent and/or metastatic head and neck squamous cell cancer, Cetuximab is administered once a week, followed by weekly doses. We present the clinical rationale of a different schedule of maintenance Cetuximab and we estimate the potential economic benefits on the health care budget from a societal perspective in Italy. Methods: A budget impact (BI) excel-based model was developed comparing a base case scenario of 100% weekly administration with a dose of 250 mg/m 2 to an every-other-week (EOW) administration at 50% or 100% with a dose of 500 mg/m 2 . Results: In the EOW, 50% scenario it was calculated a cost reduction of €347 000 of which 70% attributable to indirect costs, increasing to €694 000 after 4 months. Conclusions: In our analysis, we showed that this simplified schedule could also reduce the costs of treatments both for the health system (direct costs) and for the society (indirect costs).

Original languageEnglish
Pages (from-to)908-914
Number of pages7
JournalHead and Neck
Volume41
Issue number4
DOIs
Publication statusPublished - Apr 2019

Keywords

  • budget
  • cetuximab
  • economic benefits
  • every-other week
  • head and neck cancer

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint

Dive into the research topics of 'Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer'. Together they form a unique fingerprint.

Cite this